Phase 1 Parallel Study of CLR 125 in Triple Negative Breast Cancer

by | Dec 31, 2025 | Clinical Trials | 0 comments

​ Conditions: Breast Cancer

Interventions: Drug: Iopofosine I 131; Drug: CLR 125

Sponsors: Cellectar Biosciences, Inc.

Recruiting Conditions: Breast Cancer
Interventions: Drug: Iopofosine I 131; Drug: CLR 125
Sponsors: Cellectar Biosciences, Inc.
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *